Abstract

Background

Minimally invasive robotic surgery is a safe and effective approach for the resection of primary and metastatic liver tumors, as well as for living donor liver transplantation. However, only a limited number of centers worldwide have adopted robotic surgery for deceased donor liver transplantation. No data are available on the incidence of postoperative infections in this population.

Methods

Retrospective, observational, case-control study (1:2) in which patients who underwent minimally invasive robotic liver transplantation (RLT) from deceased donors between January and September 2024 at AOU of Modena were included. Control population was selected from patients who received deceased donor liver transplantation via laparotomy, matched for age, transplant indication, and transplantation period. Aim of the study was to compare postoperative infections and complications within the first 90 days post-transplant and median length of hospital stay between the two groups.

Results

A total of 21 patients were enrolled (7 RLT and 14 OLT). Patient characteristics are shown in Table 1. One patient per group developed CMV symptomatic infection respectively 65 and 42 post-operative days (POD) after transplantation, both treated with valganciclovir and immunosuppression reduction. Another patient in the RLT group developed oral candidiasis in POD 9, treated with oral fluconazole. In the OLT group three patients developed infections: one C.parapsilosis and E.faecium blood stream infection (BSI) in POD 1 treated with linezolid and anidulafungin, one S.sanguinis BSI in POD 1 and one K. pneumoniae ESBL urinary tract infection in POD 1 treated with ertapenem. In the OLT group, one patient underwent reoperation for biliodigestive anastomosis revision in POD 3. In the RLT group, a significant reduction in the median length of hospital stay was observed (5 versus 9 days, P = 0.001). All patients are alive and no case of graft failure occurred.

Conclusions

In our small sample, three post-operative bacterial infections developed in the OLT group within the first 90 days after transplantation and no infection in RLT group, despite the presence of patients colonized by MDR pathogens. The RLT group showed a significant reduction in the median length of hospital stay post-transplant.

Table 1.

Patient's characteristics and indication at transplant

 RLT (n = 7)OLT (n = 14)p value
Age (years), median (IQR)65 (59–71)64 (56–73)0.709
Principal indication for transplant, n (%)
HCC
Alcoholic liver cirrhosis
6 (86)
1 (14)
11 (79)
3 (21)
0.694
Second indication, n (%)
ASH e/o NASH
HCV e/o HBV
4 (57)
5 (71)
9 (64)
6 (43)
0.589
0.279
MELD Na, median (IQR)8 (6–26)11 (8–20)0.132
Child-Pugh, median (IQR)5 (5–12)7 (5–9)0.814
Charlson Comorbidity Index, median (IQR)5 (4–7)6 (4–10)0.193
BMI (Kg/m2), median (IQR)26.3 (20.1–29.4)26.0 (17.0–42.0)1.000
ESBL rectal colonization at transplant, n (%)2 (29)2 (14)0.720
VRE rectal colonization at transplant, n (%)2 (29)1 (7)0.830
ICU stay (days), median (IQR)1 (1–3)1 (0–4)0.805
LOS after transplantation (days), median (IQR)5 (4–7)9 (6–21)0.001
Total follow-up period, median (IQR)141 (79–174)180 (109–264)
 RLT (n = 7)OLT (n = 14)p value
Age (years), median (IQR)65 (59–71)64 (56–73)0.709
Principal indication for transplant, n (%)
HCC
Alcoholic liver cirrhosis
6 (86)
1 (14)
11 (79)
3 (21)
0.694
Second indication, n (%)
ASH e/o NASH
HCV e/o HBV
4 (57)
5 (71)
9 (64)
6 (43)
0.589
0.279
MELD Na, median (IQR)8 (6–26)11 (8–20)0.132
Child-Pugh, median (IQR)5 (5–12)7 (5–9)0.814
Charlson Comorbidity Index, median (IQR)5 (4–7)6 (4–10)0.193
BMI (Kg/m2), median (IQR)26.3 (20.1–29.4)26.0 (17.0–42.0)1.000
ESBL rectal colonization at transplant, n (%)2 (29)2 (14)0.720
VRE rectal colonization at transplant, n (%)2 (29)1 (7)0.830
ICU stay (days), median (IQR)1 (1–3)1 (0–4)0.805
LOS after transplantation (days), median (IQR)5 (4–7)9 (6–21)0.001
Total follow-up period, median (IQR)141 (79–174)180 (109–264)

ASH, Alcoholic Steatohepatitis; BMI, Body Mass Index; ESBL, Extended Spectrum Beta-Lactamase; HBV, Hepatitis B Virus; HCC, Hepato Cellular Carcinoma; HCV, Hepatitis C Virus; IQR, Interquartile Range; LOS, Length Of Stay; MELD, Model for End-Stage Liver Disease; NASH, Non-Alcoholic Steatohepatitis; OLT, Orthotopic Liver Transplantation; RLT, Robotic Liver Transplantation; VRE, Vancomycin Resistant Enterococcus.

Table 1.

Patient's characteristics and indication at transplant

 RLT (n = 7)OLT (n = 14)p value
Age (years), median (IQR)65 (59–71)64 (56–73)0.709
Principal indication for transplant, n (%)
HCC
Alcoholic liver cirrhosis
6 (86)
1 (14)
11 (79)
3 (21)
0.694
Second indication, n (%)
ASH e/o NASH
HCV e/o HBV
4 (57)
5 (71)
9 (64)
6 (43)
0.589
0.279
MELD Na, median (IQR)8 (6–26)11 (8–20)0.132
Child-Pugh, median (IQR)5 (5–12)7 (5–9)0.814
Charlson Comorbidity Index, median (IQR)5 (4–7)6 (4–10)0.193
BMI (Kg/m2), median (IQR)26.3 (20.1–29.4)26.0 (17.0–42.0)1.000
ESBL rectal colonization at transplant, n (%)2 (29)2 (14)0.720
VRE rectal colonization at transplant, n (%)2 (29)1 (7)0.830
ICU stay (days), median (IQR)1 (1–3)1 (0–4)0.805
LOS after transplantation (days), median (IQR)5 (4–7)9 (6–21)0.001
Total follow-up period, median (IQR)141 (79–174)180 (109–264)
 RLT (n = 7)OLT (n = 14)p value
Age (years), median (IQR)65 (59–71)64 (56–73)0.709
Principal indication for transplant, n (%)
HCC
Alcoholic liver cirrhosis
6 (86)
1 (14)
11 (79)
3 (21)
0.694
Second indication, n (%)
ASH e/o NASH
HCV e/o HBV
4 (57)
5 (71)
9 (64)
6 (43)
0.589
0.279
MELD Na, median (IQR)8 (6–26)11 (8–20)0.132
Child-Pugh, median (IQR)5 (5–12)7 (5–9)0.814
Charlson Comorbidity Index, median (IQR)5 (4–7)6 (4–10)0.193
BMI (Kg/m2), median (IQR)26.3 (20.1–29.4)26.0 (17.0–42.0)1.000
ESBL rectal colonization at transplant, n (%)2 (29)2 (14)0.720
VRE rectal colonization at transplant, n (%)2 (29)1 (7)0.830
ICU stay (days), median (IQR)1 (1–3)1 (0–4)0.805
LOS after transplantation (days), median (IQR)5 (4–7)9 (6–21)0.001
Total follow-up period, median (IQR)141 (79–174)180 (109–264)

ASH, Alcoholic Steatohepatitis; BMI, Body Mass Index; ESBL, Extended Spectrum Beta-Lactamase; HBV, Hepatitis B Virus; HCC, Hepato Cellular Carcinoma; HCV, Hepatitis C Virus; IQR, Interquartile Range; LOS, Length Of Stay; MELD, Model for End-Stage Liver Disease; NASH, Non-Alcoholic Steatohepatitis; OLT, Orthotopic Liver Transplantation; RLT, Robotic Liver Transplantation; VRE, Vancomycin Resistant Enterococcus.

This content is only available as a PDF.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.